Authors

Two Outbreaks Reveal a Dangerous Double Standard in Global Health

The stark contrast between the rapid global response to the Andes virus exposure on a cruise ship and the slower, under-resourced response to the Bundibugyo Ebola outbreak in Central Africa highlights how global health inequities—and the disproportionate burden placed on women caregivers—shape infectious disease outcomes as much as the pathogens themselves.

Defining the Characteristics of Breakthrough Invasive Fungal Infections in Hematologic Disorders

This systematic review focuses on breakthrough invasive fungal infections (bIFIs) in patients with high-risk hematological cancers, like acute leukemia, or those who have undergone stem cell transplants. Despite prophylactic antifungal treatments (usually with voriconazole or posaconazole), bIFIs remain challenging due to their complexity and high mortality rates.

Rifaquizinone: A Novel Rifamycin-Quinolone Hybrid Antibiotic

Rifaquizinone is a dual-pharmacophore antibiotic combining rifamycin and a fluoroquinolone-like compound, showing strong bactericidal activity against resistant Staphylococcus aureus strains and biofilms, with promising results for treating prosthetic joint infections (PJI) but limited oral bioavailability.

Biopreparedness Remains Vital Despite a De-Emphasis in Public Health Policy

Despite the federal government’s recent stance on pandemic planning, author Kevin Hazzard reminds us of the importance of public health work in this area.

Updates in the Treatment of Mycobacterium Tuberculosis

The latest Bench to Bedside column reviews new guidance on the treatment of drug-susceptible and drug-resistance Mycobacterium tuberculosis infections.

New Antifungal Drug Olorofim Shows Efficacy in Treating Resistant Fungal Infections

John Rex, MD, FACP, discusses the promise, precision, and challenges of this first-in-class antifungal following phase 2b trial results.

On the Frontier of Treatment-Emergent Resistance in Stenotrophomonas maltophilia

Stenotrophomonas maltophilia is an opportunistic, multidrug-resistant pathogen that poses significant treatment challenges due to its complex resistance mechanisms, limited therapeutic options, and high mortality rates among vulnerable patients.

Further Babesiosis Biology, Pathogenicity Research Underway at Yale

Pandemic Preparedness: How Immunomics Technology is Leading the Way

The COVID-19 pandemic underscored the urgent need for global pandemic preparedness. The World Health Organization (WHO) is leading efforts to establish a global treaty to address future pandemics, with findings expected in 2025. Central to this preparedness is immunomics, a field leveraging advanced genomics technologies to study the immune system at unprecedented levels of detail.

Two Outbreaks Reveal a Dangerous Double Standard in Global Health

The stark contrast between the rapid global response to the Andes virus exposure on a cruise ship and the slower, under-resourced response to the Bundibugyo Ebola outbreak in Central Africa highlights how global health inequities—and the disproportionate burden placed on women caregivers—shape infectious disease outcomes as much as the pathogens themselves.

Wiki-What? Navigating WikiGuidelines and Leveraging Their Advantages

WikiGuidelines produces novel clinical practice guidelines developed with pragmatic, applicable methodology, including a diverse author group.

Addressing Neonatal CNS Infections: Case Report of Ceftaroline Therapy in Preterm Infant With Ventriculosubgaleal Shunt

Here is a novel use of ceftaroline to treat methicillin-resistant Staphylococcus epidermidis ventriculitis in a preterm infant with a ventriculosubgaleal shunt.

From Allies to Adversaries: Antibiotics and Their Influence on Gut Microbiome

Systemic antibiotic therapy often leads to significant long-term disruptions to the gut microbiome. In addition to antibiotic stewardship, use of prebiotic fiber, fermented foods, and probiotics is a recommended strategy to minimize microbiome disruption and reestablish a healthy, diverse gut microbial population.

Antimicrobial Stewardship in the Era of Multidrug-Resistant Infections

Here are some strategies to consider for optimal utilization.

Considering Alternatives to Vancomycin for MRSA

Rachel Britt, PharmD, BCIDP, provides insights on an evolving understanding of the long-time antibiotic’s limitations for these infections and provides guidance on other agents and the role of diagnostics in finding the best agents for patients.

Infectious Diseases Provider Role in Extracorporeal Membrane Oxygenation Infections

There has been an emergence of extracorporeal membrane oxygenation-associated infections. Here is a review of how to define them and clinical management of this heterogeneous syndrome.

A Therapeutic Challenge: Quadruple-Valve Endocarditis Resulting From Injection Drug Use

Here is a case study of a patient with injection drug use, a patent foramen ovale, and recurrent MRSA bacteremia who developed rare, fatal quadruple-valve infective endocarditis involving all 4 heart valves, highlighting the high mortality risk and importance of early recognition, surgical consultation, and substance use treatment.

Drawing Borders Around a Borderless Specialty

Editor in chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the proposed OMB rule restricting federal grants for international research collaboration, and how it threatens infectious disease medicine's inherently borderless surveillance networks, publication access, and knowledge-sharing systems.

Redefining HIV Management: Emerging Antiretroviral Drug Classes and Immunologic Strategies Shaping the Future of HIV Treatment, Prevention

Several combination products are currently in development for people with HIV. Here is a review of these treatments.

Summarizing SGLT-2 Inhibitor Usage in People With Diabetes and HIV

In persons living with HIV and diabetes, the management of diabetes is lagging behind the evidence. Despite SGLT-2 inhibitors demonstrating robust clinical data in the general population, they are grossly underused in persons with HIV and diabetes.

Understanding the Current ACIP

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) was supposed to convene this week to discuss COVID-19 vaccines. However, a district court’s decision to block recent vaccine policy changes has delayed the committee's meeting amid ongoing controversy over immunization guidance and rising public health concerns such as measles outbreaks. Here is some commentary on the inner workings of the current ACIP.

What's New in 2025: From the CLSI Subcommittee on Antimicrobial Susceptibility Testing

The subcommittee approved the removal of doxycycline and tetracycline breakpoints, revised aminoglycoside breakpoints for Acinetobacter spp, and added aztreonam-avibactam breakpoints for Enterobacterales.

Intravenous Antimicrobials: Is It Time to Push?

Intravenous (IV) push is an attractive option to administer antimicrobial therapy to patients in an efficient and effective manner in a variety of clinical settings. While many advantages to IV push administration exist, clinicians should be mindful of available literature regarding safety profiles, pharmacokinetic/pharmacodynamic characteristics, and clinical data for IV push antimicrobial administration prior to utilizing it in specific patient populations.

Do You Have a Minute? Asking Infectious Diseases Clinicians to Provide Uncompensated Services

ID clinicians must be paid for time spent conducting unbillable work for OPAT services.

Cabotegravir Plus Rilpivirine Holds Up in 5 Years of Real-World Data

Jean van Wyk, MBChB, MFPM, discussed the 5-year OPERA data from IDWeek 2026 as well as the anticipated CROWN study results.

Carbapenem-Sparing Therapy for ESBL Bacteremia: New Trials, Old Questions

New data from the PETERPEN trial suggest that piperacillin-tazobactam may be noninferior to meropenem for early clinical outcomes in select patients with ESBL bloodstream infections, but carbapenems remain the standard of care until final mortality results are available and fully analyzed.

Prospective Game Changer: Lenacapavir for HIV Preexposure Prophylaxis

The twice-yearly injectable, which significantly reduces HIV incidence compared with oral regimens, has high adherence and manageable adverse effects.

Traws Advances Preclinical Oral Antiviral Program for Hantavirus, Ebola

Traws is studying an oral combination antiviral for hantavirus and Ebola, but no animal or human efficacy data have been reported.

Wiki-What? Navigating WikiGuidelines and Leveraging Their Advantages

WikiGuidelines produces novel clinical practice guidelines developed with pragmatic, applicable methodology, including a diverse author group.

Intravenous Antimicrobials: Is It Time to Push?

Intravenous (IV) push is an attractive option to administer antimicrobial therapy to patients in an efficient and effective manner in a variety of clinical settings. While many advantages to IV push administration exist, clinicians should be mindful of available literature regarding safety profiles, pharmacokinetic/pharmacodynamic characteristics, and clinical data for IV push antimicrobial administration prior to utilizing it in specific patient populations.